eli lilly oral glp-1 FDA just approved orforglipron (Foundayo), Lilly's receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest 1pt Those taking GLP-1 medications Items included:Daily Fiber+ | Daily Cortisol Support | GLP-1 Support

eli lilly oral glp-1 FDA just approved orforglipron (Foundayo), Lilly's receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest 1pt Those taking GLP-1 medications Items included:Daily Fiber+ | Daily Cortisol Support | GLP-1 Support

Those taking GLP-1 medications for diabetes and weight loss often experience gastrointestinal symptoms, but some lesser-known side effects have also been reported. MORE BELOW⬇️

Because the gastrointestinal tract rapidly degrades most plant-based peptide mimetics, and the article notes oral bioavailability data for these products is rarely published

1pt

Items included:Daily Fiber+ | Daily Cortisol Support | GLP-1 Support

Available at: Wegovy ® (semaglutide) Prescribing Information